APONTIS PHARMA AG |
Market Closed -
Other stock markets
|
After market 12:17:21 pm | |||
| 8.64 EUR | +1.17% |
|
8.63 | -0.12% |
| Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
| Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 170 | 69.7 | 39.57 | 71.14 | - | - |
| Enterprise Value (EV) 1 | 140.2 | 33.35 | 18.77 | 60.6 | 60.5 | 54.37 |
| P/E ratio | -227 x | 25.9 x | -3.57 x | 54.5 x | 19.3 x | 10.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.32 x | 1.25 x | 1.07 x | 1.39 x | 1.21 x | 1.01 x |
| EV / Revenue | 2.74 x | 0.6 x | 0.51 x | 1.18 x | 1.03 x | 0.77 x |
| EV / EBITDA | 28.8 x | 5.99 x | -1.41 x | 15.9 x | 7.66 x | 4.02 x |
| EV / FCF | 79 x | 4.31 x | -1.18 x | -5.94 x | 908 x | 8.86 x |
| FCF Yield | 1.27% | 23.2% | -84.5% | -16.8% | 0.11% | 11.3% |
| Price to Book | 4.18 x | 1.64 x | 1.31 x | 2.31 x | 2.08 x | 1.74 x |
| Nbr of stocks (in thousands) | 8,500 | 8,500 | 8,330 | 8,330 | - | - |
| Reference price 2 | 20.00 | 8.200 | 4.750 | 8.540 | 8.540 | 8.540 |
| Announcement Date | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 39.24 | 51.18 | 55.73 | 36.96 | 51.33 | 58.9 | 70.23 |
| EBITDA 1 | - | 4.862 | 5.569 | -13.28 | 3.8 | 7.9 | 13.53 |
| EBIT 1 | - | 3.116 | 3.876 | -15.16 | 1.8 | 5.167 | 9.667 |
| Operating Margin | - | 6.09% | 6.96% | -41.02% | 3.51% | 8.77% | 13.76% |
| Earnings before Tax (EBT) 1 | - | 0.2483 | 3.828 | -14.85 | 1.8 | 5.167 | 9.667 |
| Net income 1 | -1.183 | -0.7452 | 2.689 | -11.3 | 1.3 | 3.8 | 7.1 |
| Net margin | -3.01% | -1.46% | 4.82% | -30.58% | 2.53% | 6.45% | 10.11% |
| EPS 2 | - | -0.0880 | 0.3163 | -1.330 | 0.1567 | 0.4433 | 0.8367 |
| Free Cash Flow 1 | - | 1.773 | 7.742 | -15.86 | -10.2 | 0.0667 | 6.133 |
| FCF margin | - | 3.46% | 13.89% | -42.9% | -19.87% | 0.11% | 8.73% |
| FCF Conversion (EBITDA) | - | 36.48% | 139.02% | - | - | 0.84% | 45.32% |
| FCF Conversion (Net income) | - | - | 287.93% | - | - | 1.75% | 86.38% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 4/29/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q3 | 2022 S1 | 2024 Q1 | 2024 Q2 |
|---|---|---|---|---|---|
| Net sales 1 | 24.01 | 12.69 | - | 10.5 | 9.8 |
| EBITDA | - | 1.566 | - | - | 0.9 |
| EBIT | - | 1.227 | - | - | - |
| Operating Margin | - | 9.67% | - | - | - |
| Earnings before Tax (EBT) | - | - | 2.389 | - | - |
| Net income | -2.197 | - | 2.351 | - | - |
| Net margin | -9.15% | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/11/21 | 11/18/21 | 8/11/22 | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 29.8 | 36.3 | 20.8 | 10.5 | 10.6 | 16.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 1.77 | 7.74 | -15.9 | -10.2 | 0.07 | 6.13 |
| ROE (net income / shareholders' equity) | - | 7.95% | 6.54% | -31.5% | 4.17% | 11% | 18.2% |
| ROA (Net income/ Total Assets) | - | - | 4.72% | -19.3% | 2.7% | 6.9% | 12.2% |
| Assets 1 | - | - | 56.99 | 58.66 | 48.15 | 55.07 | 58.2 |
| Book Value Per Share 2 | - | 4.790 | 4.990 | 3.630 | 3.700 | 4.100 | 4.900 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 1.66 | 3.28 | 3.26 | 4.17 | 6.5 | 4.9 |
| Capex / Sales | - | 3.24% | 5.88% | 8.83% | 8.12% | 11.04% | 6.98% |
| Announcement Date | 4/29/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.54
EUR
Average target price
17.5
EUR
Spread / Average Target
+104.92%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +81.89% | 77.41M | |
| +43.48% | 750B | |
| +34.11% | 606B | |
| -6.27% | 356B | |
| +18.84% | 326B | |
| +6.55% | 286B | |
| +18.08% | 246B | |
| -3.44% | 213B | |
| +11.35% | 213B | |
| +2.29% | 167B |
- Stock Market
- Equities
- APPH Stock
- Financials Apontis Pharma AG
